Overview
Neumora Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to brain diseases, with a pipeline targeting depression, schizophrenia, and other psychiatric disorders through novel receptor-targeted mechanisms. Their lead asset navacaprant is a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
South San Francisco, USA
Funding
Public · NASDAQ: NRXS
Website
www.neumoratherapeutics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →